ClinicalTrials.gov
ClinicalTrials.gov Menu

GLP-1: Acute Effects on Kidney Function in Healthy Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01333163
Recruitment Status : Completed
First Posted : April 11, 2011
Last Update Posted : December 15, 2011
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
Jeppe Skov, University of Aarhus

April 8, 2011
April 11, 2011
December 15, 2011
May 2011
December 2011   (Final data collection date for primary outcome measure)
Glomerular Filtration Rate [ Time Frame: Every 20 minutes for 6 hours ]
Same as current
Complete list of historical versions of study NCT01333163 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GLP-1: Acute Effects on Kidney Function in Healthy Men
GLP-1: Acute Effects on Kidney Function in Healthy Men
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
Not Provided
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Kidney Functional
  • Biological: Human GLP-1 (7-36) amide
    2 hour IV infusion, 1,5pmol/min/kg.
  • Biological: Isotone NaCl
    2 hours IV infusion.
  • Active Comparator: GLP-1
    Intervention: Biological: Human GLP-1 (7-36) amide
  • Placebo Comparator: Placebo
    Intervention: Biological: Isotone NaCl
Skov J, Dejgaard A, Frøkiær J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013 Apr;98(4):E664-71. doi: 10.1210/jc.2012-3855. Epub 2013 Mar 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
Same as current
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy young men

Exclusion Criteria:

  • Any chronic diseases
Sexes Eligible for Study: Male
18 Years to 30 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT01333163
VEKRM 29414
Yes
Not Provided
Not Provided
Jeppe Skov, University of Aarhus
Jeppe Skov
Novo Nordisk A/S
Principal Investigator: Jeppe Skov, MD University of Aarhus
University of Aarhus
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP